Valiant Laboratories (NSE:VALIANTLAB) Piotroski F-Score: 3 (As of Jun. 26, 2026) — 25% Below Median


NSE:VALIANTLAB Valiant Laboratories Ltd NSE:VALIANTLAB
51 GF Score
Price ₹68.00
GF Value ₹103.25
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Valiant Laboratories Piotroski F-Score?

Valiant Laboratories NSE:VALIANTLAB -0.06% 51 Piotroski F-Score is 3 as of Jun. 26, 2026, which is 25% below its 10-year median of 4.00. GuruFocus rates NSE:VALIANTLAB with a GF Score™ of 51/100 and a GF Value™ of ₹103.25 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 981 Drug Manufacturers companies, Valiant Laboratories ranks worse than 78.29% on this metric.

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Valiant Laboratories has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Valiant Laboratories's Piotroski F-Score or its related term are showing as below:

NSE:VALIANTLAB' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 4   Max: 6
Current: 3

During the past 6 years, the highest Piotroski F-Score of Valiant Laboratories was 6. The lowest was 3. And the median was 4.

Valiant Laboratories  (NSE:VALIANTLAB) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Valiant Laboratories Piotroski F-Score Related Terms


Valiant Laboratories Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Valiant Laboratories's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valiant Laboratories Piotroski F-Score Chart

Valiant Laboratories Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Piotroski F-Score
Get a 7-Day Free Trial N/A 5.00 6.00 3.00 3.00

Valiant Laboratories Quarterly Data
Mar21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 0.00 0.00 0.00 3.00

NSE:VALIANTLAB vs ZTS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Valiant Laboratories's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valiant Laboratories Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Valiant Laboratories's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Valiant Laboratories's Piotroski F-Score falls into.


NSE:VALIANTLAB
51GF Score
Valiant Laboratories Ltd NSE:VALIANTLAB
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was ₹-33 Mil.
Cash Flow from Operations was ₹-104 Mil.
Revenue was ₹2,375 Mil.
Gross Profit was ₹403 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was (4008.575 + 4639.766) / 2 = ₹4324.1705 Mil.
Total Assets at the begining of this year (Mar25) was ₹4,009 Mil.
Long-Term Debt & Capital Lease Obligation was ₹289 Mil.
Total Current Assets was ₹2,283 Mil.
Total Current Liabilities was ₹1,194 Mil.
Net Income was ₹-22 Mil.

Revenue was ₹1,334 Mil.
Gross Profit was ₹168 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was (3426.873 + 4008.575) / 2 = ₹3717.724 Mil.
Total Assets at the begining of last year (Mar24) was ₹3,427 Mil.
Long-Term Debt & Capital Lease Obligation was ₹1,046 Mil.
Total Current Assets was ₹1,926 Mil.
Total Current Liabilities was ₹596 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Valiant Laboratories's current Net Income (TTM) was -33. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Valiant Laboratories's current Cash Flow from Operations (TTM) was -104. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-32.679/4008.575
=-0.00815227

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-22.012/3426.873
=-0.00642335

Valiant Laboratories's return on assets of this year was -0.00815227. Valiant Laboratories's return on assets of last year was -0.00642335. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Valiant Laboratories's current Net Income (TTM) was -33. Valiant Laboratories's current Cash Flow from Operations (TTM) was -104. ==> -104 <= -33 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=288.907/4324.1705
=0.06681212

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=1046.002/3717.724
=0.28135547

Valiant Laboratories's gearing of this year was 0.06681212. Valiant Laboratories's gearing of last year was 0.28135547. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=2283.234/1194.458
=1.91152305

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=1926.179/596.157
=3.23099284

Valiant Laboratories's current ratio of this year was 1.91152305. Valiant Laboratories's current ratio of last year was 3.23099284. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Valiant Laboratories's number of shares in issue this year was 64.076. Valiant Laboratories's number of shares in issue last year was 43.161. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=403.04/2374.675
=0.16972428

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=167.822/1333.82
=0.12582058

Valiant Laboratories's gross margin of this year was 0.16972428. Valiant Laboratories's gross margin of last year was 0.12582058. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=2374.675/4008.575
=0.5923988

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=1333.82/3426.873
=0.38922364

Valiant Laboratories's asset turnover of this year was 0.5923988. Valiant Laboratories's asset turnover of last year was 0.38922364. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+0+1+0+0+1+1
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Valiant Laboratories has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 3 mean?
Valiant Laboratories (NSE:VALIANTLAB) has a Piotroski F-Score of 3 as of Jun. 26, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Valiant Laboratories and its competitors. This is 25% below median its historical median of 4.00. Over the past decade, Valiant Laboratories' Piotroski F-Score has ranged from 3.00 to 6.00. According to the industry distribution chart, Valiant Laboratories ranks #768 out of 981 companies in the Drug Manufacturers industry, placing it in the top 78.3%.
Is Valiant Laboratories' Piotroski F-Score too high?
Valiant Laboratories' current Piotroski F-Score of 3 is 25% below median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 6.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Valiant Laboratories' value of 3 is 40% below this industry median. Based on the distribution chart, Valiant Laboratories ranks #768 out of 981 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Valiant Laboratories has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valiant Laboratories' Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Valiant Laboratories ranks #768 out of 981 companies for Piotroski F-Score. This places Valiant Laboratories in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Valiant Laboratories' value of 3 is 40% below this benchmark. Historically, Valiant Laboratories' own Piotroski F-Score has ranged from 3.00 to 6.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Valiant Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valiant Laboratories's current Piotroski F-Score of 3 is 40% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Valiant Laboratories and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valiant Laboratories's current Piotroski F-Score is 3, which is 25% below median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valiant Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Valiant Laboratories (NSE:VALIANTLAB) is currently considered Possible Value Trap. The stock's GF Value™ is ₹103.25, compared to a current price of ₹68.00 — trading 34.1% below its estimated fair value. The current Piotroski F-Score is 3, which is 25% below median its 10-year median of 4.00 and 40% below the Drug Manufacturers industry median of 5.00. Valiant Laboratories' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Valiant Laboratories (NSE:VALIANTLAB), the current Piotroski F-Score is 3 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Valiant Laboratories (NSE:VALIANTLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Valiant Laboratories stock appears to be undervalued. The current stock price of ₹68.00 is trading 34.1% below its estimated GF Value™ of ₹103.25. GuruFocus considers Valiant Laboratories to be Possible Value Trap.

Key valuation signals for NSE:VALIANTLAB:

  • Piotroski F-Score: 3 (25% below median its 10-year median of 4.00)
  • GF Value™: ₹103.25 vs. price of ₹68.00 (34.1% below fair value)
  • GF Score™: 51/100 with 5 warning signs
  • Industry Position: 40% below the Drug Manufacturers median (#768 of 981)

No single metric tells the full story. See the NSE:VALIANTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Valiant Laboratories Business Description

Other Exchanges 543998:India
Address Mulund Goregaon Link Road, 104, Udyog Kshetra, Mulund, MH, IND, 400080
Valiant Laboratories Ltd is an Active Pharmaceutical Ingredient (API)/Bulk Drug manufacturing company with having focus on manufacturing Paracetamol. Paracetamol is one of the widely used analgesics globally and is recommended as the first-line therapy in pain conditions by the World Health Organization. Paracetamol has several applications such as usage in the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. It manufactures Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers.
51GF Score

Get the complete analysis for NSE:VALIANTLAB

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹68.00
Price
₹103.25
GF Value